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Abstract
Background: Aggregation of malformed proteins is a key feature of many neurodegenerative diseases, but the
mechanisms that drive proteinopathy in the brain are poorly understood. We aimed to characterize aggregated
proteins in human brain tissues affected by dementia.
Results: To characterize amyloidal plaque purified from post-mortem brain tissue of dementia patient, we applied
ultracentrifugation-electrostatic repulsion hydrophilic interaction chromatography (UC-ERLIC) coupled mass
spectrometry-based proteomics technologies. Proteomics profiling of both soluble and aggregated amyloidal plaque
demonstrated significant enrichment and deamidation of S100A9, ferritin, hemoglobin subunits, creatine kinase and
collagen protein among the aggregated brain proteins. Amyloidal plaques were enriched in the deamidated variant of
protein S100A9, and structural analysis indicated that both the low- and high-affinity calcium binding motifs of S100A9
were deamidated exclusively in the aggregated fraction, suggesting altered charge state and function of this protein in
brain tissues affected by dementia. The multiple deamidated residues of S100A9 predicts introduction of negative
charge that alter Ca++ binding, suggesting increased capacity to form pathological aggregates in the brain.
Conclusion: UC-coupled proteomics revealed that brain amyloidal plaques are enriched in deamidated proteins, and
suggested that altered charge state and calcium-binding capacity of S100A9 may enhance protein aggregation and
promote neurodegeneration in the human brain.
Keywords: Neurodegenerative disease, Amyloids, Deamidation, Brain Proteome, Protein S100A9, Mitochondrial creatine
kinase
Background
Proteinopathy is caused by the aggregation of malformed
proteins (amyloids) to form insoluble plaques in the brain,
leading to neurodegenerative pathology in disorders in-
cluding Alzheimer’s disease (AD), Parkinson’s disease (PD),
and Huntington’s disease (HD) [1, 2]. Accumulation of
abnormally-folded tau protein and amyloid plaque forma-
tion are typical features of AD [2, 3], while accumulation of
α-synuclein protein triggers death of dopamine-generating
cells in the substantia nigra of PD patients [4], and intracel-
lular aggregates of Huntingtin (Htt) protein causes HD [5].
Accordingly, it is now widely accepted that changes in
brain protein function and aggregation are key features of
multiple neurodegenerative diseases, but the specific
protein modifications that first initiate and promote plaque
formation are poorly defined [6]. In order to pave the way
for effective new therapies that can protect against protei-
nopathy and disrupt neurodegeneration in human patients,
it will first be necessary to identify the key disease-
associated changes in protein relative abundance, solubility,
and neurotoxicity in human brain tissues affected by
dementia.
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Accurate identification and quantitation of amyloid pro-
teins in brain tissue extracts is technically challenging due
to the ability of these molecules to self-associate and form
multiple variants, each with distinct properties and variable
solubility [7]. However, overcoming these technical difficul-
ties will be vital to understanding the biological basis of
synapse loss and human cognitive impairment, which has
already been linked with the accumulation of soluble
neurotoxic amyloids in the brain [8]. Accordingly, we
sought to optimize a protocol for the isolation of both
soluble and aggregated amyloid proteins from human brain
tissues for quantitative proteomic analysis. Previous at-
tempts have studied amyloid proteins using detergents/de-
tergent-free buffers together with sequential extraction and
quantification by ELISA, immunoblotting, or immunocyto-
chemistry [9–11], but these approaches are unable to deter-
mine the aggregation state of the amyloids. More rarely,
attempts have been made to determine the complete com-
position of amyloid plaques and to understand how the
constituent proteins contribute to plaque formation, but
this method disregards any involvement of non-amyloid
proteins in the aggregation process. Our strategy was there-
fore to use mass spectrometry-based proteome-wide profil-
ing of both the soluble and aggregated fractions of human
brain tissues affected by dementia, thereby shedding new
light on potential mechanisms of protein aggregation and
plaque formation in common neurodegenerative diseases.
The human brain proteome is extremely complex and
requires robust techniques to enable accurate protein
identification and high proteome coverage. Ultracentri-
fugation (UC) is a very effective method of sample
sedimentation that facilitates the recovery of aggregated
proteins and small particles including ribosomes,
extracellular vesicles, viruses and rare protein variants
from heterogeneous biological materials [12, 13]. After
sample processing, electrostatic repulsion-hydrophilic
interaction chromatography (ERLIC) can be used to
fractionate the sample and facilitate separation of pep-
tide isoforms with different charges such as deamidated
peptides by mass spectrometry. The objective of our
study was to use this combined UC-ERLIC approach to
conduct a comprehensive proteomic analysis of human
brain tissue samples and identify dementia-associated
changes in amyloid protein composition, relative abun-
dance, and extent of deamidation. Our data reveal that
amyloid plaque formation is associated with protein
deamidation in human brain tissue. We identified
specific proteins that were deamidated only in the in-
soluble aggregates, and structural modeling of these
modified proteins predicted changes in charge state and
ion binding potential that would be expected to pro-
mote aggregation. This study reports for the first time
that human brain proteins exhibit extensive deamida-
tion in dementia-associated amyloidosis, and suggests
that deamidation promotes protein aggregation and amyl-
oid plaque formation in human neurodegenerative disease.
Results
Optimizing brain protein extraction to prevent sample
aggregation ex vivo
Amyloidosis is the process by which malformed proteins
aggregate and form insoluble plaques in body tissues,
eventually leading to impaired organ function. While
amyloidosis has been implicated in the pathology of
more than 20 major human diseases, including several
neurodegenerative disorders, the variable composition
and solubility of amyloid deposits have so far prevented
detailed analysis of their role in human cognitive impair-
ment. We therefore sought to develop robust methods
to facilitate proteomic analyses of human brain tissues
and identify disease-associated changes in the brain
proteome that might shed new light on the process of
amyloidosis in human neurodegeneration. In order to
accurately identify brain proteins that undergo aggrega-
tion in vivo, it is essential to prevent artifactual protein
aggregation during sample processing in vitro. Since
protein aggregation and structural modifications are pH-
sensitive events that can be triggered by inappropriate
buffer use, we first tested the efficiency of protein ex-
traction from brain tissue samples using a range of
mildly acidic and alkaline buffers (AAB, ABB and TEAB;
see methods) at various different temperatures (10, 22
and 37 °C) for variable duration (1, 3 or 7 days). The ex-
tracted soluble and aggregated proteins in all prepara-
tions were measured and analyzed by LC-MS/MS. We
observed that optimal protein extraction was achieved
using mild detergent (2 % SDS) together with a weak
acid pH buffer (AAB, pH 6.0), which generated a high
total protein yield, restricted sample aggregation during
processing, and protected against structural changes in
vitro. These data demonstrated that via extensive proto-
col optimization, it is possible to conduct robust prote-
omic analyses of primary human brain tissues, thereby
facilitating the identification of specific amyloids,
changes in plaque composition, and structural modifica-
tions of brain proteins that might promote amyloidosis
and/or disease progression in human neurodegenerative
disorders.
Enrichment of human brain amyloidal proteins
Protein aggregation into amyloid plaques is a pathologic
hallmark of multiple neurodegenerative diseases, but
therapies directed against amyloid proteins have shown
little clinical benefit in human patients so far, suggesting
a critical role for non-amyloid proteins in the formation
of plaques. Having optimized our protocol for extraction
of both soluble and aggregated proteins from post-
mortem samples of human brain, we next conducted a
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proteome-wide analysis of amyloid structure, relative
abundance and plaque composition in human brain tis-
sues affected by dementia. To do this, we extracted both
soluble and aggregated amyloidal proteins from brain
using our UC-based method, subjected the aggregated
proteins to further extraction and solubilization in for-
mic acid (FA), and separated the deamidated peptides by
ERLIC fractionation and structural analysis by LC-MS/
MS. Using this approach, we identified a total of 5225 ±
248 brain tissue proteins, of which 4339 ± 104 individual
proteins remained after application of a stringent false-
discovery rate (FDR; cutoff value <1.0 %) and the charac-
terized proteins have been identified with at least 2
unique peptides. Overlap analysis revealed that while
1697 proteins were present in both the soluble and
aggregated fractions, 159 individual brain proteins were
specific to the aggregated (pellet) fraction only (Fig. 1).
We observed significant enrichment of S100A9, ferritin,
mitochondrial creatine kinase (U-type), and hemoglobin
subunits (α, β, ε and ζ) within the protein aggregate
(Fig. 2a, b), as well as increased abundance of collagen,
palmitoyl-protein thioesterase 1, laminin, coronin-1A,
S100-B, S100-A8, Syntaxin-binding protein 2, cathepsin
G, grancalcin, and syntaxin-binding protein 2 (Additional
file 1: Table S1A–D). While protein S100A9 was present
in both sample types, the levels detected in the pellet frac-
tion (protein score 5083.50 ± 172.50, emPAI 300.74 ± 0.00)
were far higher than those detected in the soluble fraction
(1315.50 ± 119.50; 8.81 ± 0.00), suggesting substantial en-
richment of S100A9 in brain amyloid aggregates (Fig. 2,
Additional file 2: Table S2 and Additional file 1: Table S1C).
Similarly, the iron-storing protein ferritin was also enriched
in the pelleted protein aggregate (emPAI 450.45 ± 0.00)
relative to the levels detected in the soluble fraction (15.20
± 0.00; Fig. 2b). Also enriched in the pellet fraction were
the hemoglobin subunits α, β, ε and ζ, consistent with
reports that elevated hemoglobin levels are associated with
increased risk of neurodegenerative disease and rapid
cognitive decline (Additional file 2: Table S2 and Additional
file 1: Table S1D). Conversely, a distinct subset of brain pro-
teins was more abundant in the soluble fraction than in the
pellet, including neuromodulin, glial fibrillary acidic protein,
myelin basic protein isoform 4, synaptosomal associated
protein 25, brain acid soluble protein 1, and components of
β-tubulin (Fig. 3a and b). After further separation of the
soluble fraction by UC-ERLIC, we were also able to detect
several different isoforms of APBB2 and amyloid-like
protein APLP2, as well as APBB1, APBB1IP and SAA4.
These data indicated that multiple amyloid-like protein
isoforms displayed only intermediate levels of aggregation
and were therefore largely absent from the pellet fraction
(Fig. 4).
Brain protein deamidation in dementia
Accumulation of structural modifications that impair pro-
tein function is a common feature of multiple age-related
pathologies including major neurodegenerative diseases.
Alterations including deamidation, racemerization and gly-
cation have all been reported to disrupt normal protein
function, and deamidation in particular is known to induce
major perturbations in protein structure, folding/topology
and overall stability. In the current study, we observed
Fig. 1 Venn diagram showing overlap of the brain proteins identified in the soluble and aggregated fractions. Proteins were extracted using
acetate buffer pH 6.0 with detergent
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Fig. 2 Protein abundance in the aggregated fraction of the human brain proteome as extracted using detergent/acetate buffer together with
ultracentrifugation/ERLIC fractionation (a). Embedded panel details the most abundant proteins detected in the aggregated fraction (b)
Fig. 3 Protein abundance in the soluble fraction of the human brain proteome as extracted using detergent/acetate buffer together with
ultracentrifugation/ERLIC fractionation (a). Embedded panel details the most abundant proteins detected in the soluble fraction (b)
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extensive deamidation of brain proteins in the pelleted
insoluble aggregate, including S100A9, ferritin, hemoglobin,
creatine kinase (U-type), S100-B, collagen α-2(IV) chain,
collagen α-2(I) chain, laminin subunit β-2, dystonin (iso-
form 3), and serine/threonine-protein kinase (isoform 2)
(Additional file 2: Table S3 and Additional file 1: Table
S1E). We also detected deamidation of proteins coronin-1A
and syntaxin-binding protein 2, which have previously been
implicated in neurodegeneration of the hippocampus. Im-
portantly, the presence of deamidated proteins was not
restricted to the aggregated pellet, since the soluble brain
proteome also exhibited extensive deamidation of creatine
kinase B. In parallel, we observed that mitochondrial creat-
ine kinase was highly enriched in the pellet and deamidated
exclusively within the aggregate, suggesting that organelle
dysfunction and compromised energy metabolism may be a
feature of brain plaque formation and neurodegeneration.
Many specific deamidation sites were exclusively identi-
fied in the aggregated proteins, including modifications of
S100A9, ferritin, hemoglobin subunits, S100-A8, S100-B,
collagens, mitochondrial creatine kinase (U-type), β-tubulin
and laminin. The deamidation sites of protein S100A9 that
were commonly identified in Mascot and Maxqunat were
listed in Table 1. These specific structural modifications
may have functional consequences that influence the pro-
gression of neurodegenerative diseases. For example, the
inflammation-associated calcium binding protein S100A9
incorporates two EF-hand motifs that exhibit differential
Fig. 4 Relative abundance of different forms of APP in the soluble and aggregated protein fractions of the human brain proteome
Table 1 S100A9 peptide sequences and deamidation sites commonly identified in Mascot and Maxqunat that were highly enriched
among the aggregated brain proteins
Protein accession number Protein description Peptide sequence and site
of modification (Mascot)
Peptide sequence and site
of modification (Maxquant)
P06702 Protein S100-A9 K.LGHPDTLN#QGEFK.E KLGHPDTLN#QGEFKE
P06702 Protein S100-A9 K.LGHPDTLNQ#GEFKELVR.K KLGHPDTLNQ#GEFKE
P06702 Protein S100-A9 K.VIEHIMEDLDTN#ADK.Q VIEHIMEDLDTN#ADK
P06702 Protein S100-A9 R.N#IETIINTFHQYSVK.L NIETIINTFHQ#YSVK
P06702 Protein S100-A9 R.NIETIIN#TFHQYSVK.L NIETIIN#TFHQYSVK
P06702 Protein S100-A9 R.NIETIINTFHQ#YSVK.L NIETIINTFHQ#YSVK
P06702 Protein S100-A9 R.N#IETIINTFHQYSVK.L N#IETIINTFHQYSVK
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affinity for Ca++ binding, and deamidation of both motifs
was detected exclusively in the aggregated fraction (Fig. 5).
In contrast, only low levels of S100A9 were detected in the
soluble fraction and the protein was not deamidated in this
sample. These data suggest that deamidation and aggrega-
tion of brain proteins that regulate inflammatory processes
may contribute to the pathology of human neurodegenera-
tion. While these data suggested that protein deamidation
and aggregation are key features of brain plaque formation,
we also detected the restorative enzyme PIMT (ProteinL-
isoaspartate O-methyltransferase) within the pellet aggre-
gate, perhaps indicating a failed response to repair disrupted
protein functions. In vitro incubation of protein samples at
various different temperatures (10, 22 and 37 °C) for
variable duration (1, 3 or 7 days) in different buffers like
AAB (pH 6), ABB (pH 8) and TEAB (pH 8.5) revealed
precipitation of protein except acetate buffer (pH 6). As
alkaline condition is known to induce protein deamidation,
this observation may suggest that deamidation causes
aggregation of proteins.
Discussion
Aggregation of brain proteins is thought to be a key fea-
ture of human neurodegenerative diseases. While some
studies have successfully linked protein plaque formation
with disease severity [14, 15], other investigators have
failed to confirm this correlation [16, 17], perhaps be-
cause amyloid deposition represents an early event that
precedes clinical symptoms [18], or possibly due to key
biochemical changes occurring outside the plaques. In-
deed, soluble amyloid oligomers can form even in the
brains of cognitively normal individuals where they are
known to be highly neurotoxic [19], and there is exten-
sive evidence to suggest that non-plaque, water-soluble
amyloids contribute to the pathology of neurodegenera-
tive pathology [20]. Previous studies have reported that
levels of soluble amyloid detected by Western blotting
are significantly correlated with frequency of neuritic
plaques and neurofibrillary tangles in AD [21]. Similarly,
Naslund et al., observed no link between plaque number
and cognitive impairment in their study of patients with
dementia, but the quantity of the insoluble amyloid
plaque did correlate with declining brain function [22].
While previous studies have sought to quantify specific
isoforms of soluble amyloids using ELISA analysis of
mouse and human brain tissues [9, 11], the potential
role played by these proteins in the neurodegenerative
process has remain unclear (reviewed in [23]). By apply-
ing an unbiased discovery-based proteomics approach in
the current study, we now provide the first comprehen-
sive profile of both the soluble and aggregated fractions
of the human brain proteome in dementia, and we
present evidence that deamidation leading to impaired
protein function may play a significant role in disease
pathology.
Deamidation adds a negative charge at sites of modifica-
tion and thereby promotes protein aggregation, which is a
pathological hallmark of several age-related disorders and
common neurodegenerative diseases [24–29]. Accordingly,
protein deamidation has been strongly implicated in the
pathogenesis of dementia syndromes [30, 31], and in the
current study we observed that deamidation was a com-
mon feature of aggregated brain proteins including ferritin,
S100 family members, hemoglobin subunits, collagens,
mitochondrial creatine kinase (U-type), β-tubulin and lam-
inin. Collagen type XXV is a key component of amyloid-
containing plaques in the brains of patients with neurode-
generative diseases [32], and here we observed deamidation
of collagen chains α-2(IV) and α-2(I) which might be pre-
dicted to increase aggregation. Furthermore, we detected
significant enrichment of ferritin in aggregated proteins
from brain tissues affected by dementia, consistent with
previous reports that increased ferritin iron is associated
with neurodegenerative pathology [33]. It is possible there-
fore that deamidation and aggregation of ferritin leads to
Fig. 5 Structural model of Protein S100A9 (RCSB Protein Data Bank
accession code: 1XK4) showing deamidation sites. EF hand calcium
binding motifs are shown in yellow and deamidation sites (area of
modification) are highlighted in magenta and blue. Helices are
shown in green while Ca ions are shown as red spheres. Lower
panel shows only EF hands and area of modification with Ca ions
in green
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increases in iron content in the brain during neurodegener-
ation. These data suggest that protein functional impair-
ment due to deamidation of key residues may have a major
role to play in shaping neurodegenerative pathology. In-
deed, a previous study has reported that deamidation
contributes to insolubilization and aggregation of lens pro-
tein crystallins during cataract formation [34].
It has been reported that AD patients exhibit decreased
expression of creatine kinase (U-type) in the brain, sug-
gesting altered energy metabolism in affected tissues [35].
In the current study we instead observed substantial
enrichment of this enzyme in the pellet fraction, although
the protein also exhibited marked deamidation in the
aggregate, suggesting that normal metabolic function may
be disrupted even when creatine kinase levels are normal.
Formation of creatine kinase crystalline inclusions has
been identified in the mitochondria of cells subjected to
ischemia [36]. The presence of these inclusion bodies is
associated with oxidative adaptation to restriction of en-
ergy supply, and is a clinical hallmark of mitochondrial
cytopathy in multiple neuropathologies including demen-
tia [37, 38]. Deamidation of creatine kinase B is also asso-
ciated with loss of enzyme activity in PIMT knockout
mice [38, 39], which exhibit severe neuropathology with
rapid onset after birth. In the current study, we identified
high levels of PIMT in the insoluble protein pellet fraction,
suggesting that aggregation of this enzyme disrupts a key
mechanism of protection against further protein deamida-
tion (as has already been reported in aging brain tissues in
both human and animal models [40, 41]). However, it is
important to note that among the identified proteins
already implicated in dementia pathology, many were
enriched in the soluble fraction rather than the aggregated
pellet (including GFAP, GAP43, MBP, SNAP25, BASP1,
IGKC, TUBB4B, TBB8L, TUBB4A [42–44]), suggesting
that full elucidation of disease pathogenesis will require a
better understanding of changes in brain protein structure
and function outside of the plaque.
In our study of human brain tissue affected by demen-
tia, we observed that the pelleted aggregate was signifi-
cantly enriched in the demidated protein S100A9,
consistent with reports that knockdown of S100A9 can
restore cognitive function and reduce amyloid plaque
burden in the Tg2576 mouse model of AD [45]. In line
with these findings, it has previously been proposed that
S100A9 promotes the formation of β-amyloid aggregates
[19], although the molecular mechanism by which this
proteinopathy might be initiated remains unknown. By
mapping the deamidation sites identified onto the 3D
structure of S100A9, we observed that both the low- and
high-affinity calcium binding motifs that characterize
this protein [46] were deamidated only in the aggregated
fraction. Since deamidation is thought to introduce
negative charge to the modified sites of the affected
protein [30, 31], deamidation of the S100A9 calcium bind-
ing sites could therefore be predicted to promote protein
aggregation and amyloid formation in the brain. S100A9
composed of two EF-hand motifs: the N-terminal motif
comprising helices I and II, and, separated by a flexible
linker, the C-terminal motif with helices III and IV, thus
providing two Ca2+-binding sites. The details of the struc-
ture have been described by Itou et al. [47] and Korndör-
fer et al. [46]. Deamidation is a spontaneous process and
validation of deamidation at specific sites is very much
challenging due to lack of commercial antibodies. How-
ever, when proteins were incubated in vitro at various
different temperatures (10, 22 and 37 °C) for variable dur-
ation (1, 3 or 7 days) in different buffers like AAB (pH6),
ABB (pH8) and TEAB (pH8.5), we found precipitation of
proteins in alkaline buffers, but not in acetate buffer at
(pH 6.0). As protein is prone to deamidation at pH > 7,
this support that protein deamidation causes aggregation
of proteins. Secretion of S100A9 during inflammation has
previously been reported to enhance the formation of
amyloid plaques [19], and our data now suggest that
deamidation of this protein could be a key event in amyl-
oidosis in the human brain. Novel therapies that prevent
deamidation of brain proteins such as S100A9 could
therefore represent an effective approach to the treatment
of human neurodegenerative diseases.
Conclusions
Localized deposition of amyloid protein in the brain is an
invariant and defining feature of several neurodegenerative
diseases. Previous attempts to characterize human amyloi-
dal plaque composition have been infrequent and met with
only limited success. We therefore developed a novel ap-
proach (UC-ERLIC) to the isolation of both soluble and ag-
gregated amyloidal proteins from human brain tissues and
subjected these to comprehensive proteomic profiling. This
study demonstrated significant enrichment and deamida-
tion of S100A9, ferritin, hemoglobin subunits, and myelin
basic protein among the aggregated brain proteins. Protein
S100A9 was highly abundant in the amyloidal plaque
samples, and structural analysis indicated that both the
low- and high-affinity calcium binding motifs of S100A9
were deamidated exclusively in the aggregated fraction,
suggesting altered charge state and function of this protein
in brain tissues affected by dementia. Together, these data
reveal for the first time that deamidation of S100A9 may
represent a key mechanism that triggers protein aggrega-
tion and amyloid formation in the human brain.
Methods
Extraction of soluble and aggregated proteins from
human brain tissue
Sequencing-grade modified trypsin (V5111) was from
Promega (Madison, WI, USA). Protease inhibitor cocktail
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tablets (cOmplete) were from Roche (Basel, Switzerland).
All other chemicals and reagents were from Sigma–Al-
drich (St. Louis, MO, USA) unless otherwise stated. Post-
mortem brain tissue samples of a 69-year-old male diag-
nosed with subarachnoid hemorrhage and dementia issues
were obtained from the brain bank of the Choju Medical
Institute of the Fukushimura hospital (Toyohashi, Aichi,
Japan), and the protocols utilized were approved by the
local ethics committee of the Fukushimura hospital. The
scientific use of human material was conducted in accord-
ance with the Declaration of Helsinki, and informed
consent was obtained from the guardians of the patients
[48]. All procedures were approved and performed in ac-
cordance with the ethical guidelines of the Nanyang
Technological University ethics board. The tissue was first
dissected, the large blood vessels removed, and the re-
mainder cut into small pieces and homogenized. In initial
experiments, we used 12.5 ml ice-cold homogenization
buffer (2 % w/v SDS, 20 mM Tris–HCl, pH 7.4) supple-
mented with Roche cOmplete protease inhibitor cocktail.
In later experiments, protein sample processing was per-
formed under mildly acidic conditions (2 % SDS, 50 mM
ammonium acetate buffer, pH 6.0) in order to minimize
deamidation artifacts and eliminate false positive identifi-
cation [49]. After tissue homogenization, cell debris was
removed by centrifugation at 3000 × g, 10 °C for 10 min,
then the supernatant was ultracentrifuged at 112000 × g,
10 °C for 1 h. The resultant supernatant was collected and
subjected to two further rounds of ultracentrifugation at
112000 × g, 10 °C for 1 h. The amyloid-enriched pellets
generated by these two ultracentrifugation steps were
combined and re-suspended in 12.5 ml mild acid buffer
(2 % SDS, 50 mM ammonium acetate buffer (AAB),
pH 6.0) and then mixed and ultracentrifuged at 112000 × g,
10 °C for 1 h. The supernatants generated by each of the
ultracentrifugation steps were pooled for later analysis. The
pellet containing the insoluble amyloidal plaque was re-
suspended in 1 ml formic acid (FA; 70 %), then vortexed
for 2 min, and centrifuged for 15 min at 18000 × g, 4 °C. To
ensure complete dissolution, the final sample pellet was re-
suspended in 1 ml FA (99 %), vortexed for 2 min, and
centrifuged at 18,000 × g, 4 °C for 10 min. To support
protein deamidation causes protein aggregation, in vitro ex-
tracted protein were incubated in buffers like ammonium
acetate buffer (AAB, 50 mM, pH 6.0), triethylammonium
bicarbonate (TEAB, 50 mM, pH8.5), ammonium bicarbon-
ate buffer (ABB, 50 mM, pH 8.0), at different temperatures
(10, RT (22 °C) and 37 °C) and different durations (day 1,
day 3 and day 7).
Sample preparation and LC-MS/MS analysis
Proteins were reduced with dithiothreitol (10 mM), alky-
lated using iodoacetamide (55 mM) and then subjected to
overnight digestion in sequencing-grade modified trypsin
at 37 °C. Tryptic peptides were fractionated by ERLIC
separation on an amine-column using a Shimadzu Prom-
inence UFLC system. Mobile phase A (85 % acetonitrile,
0.1 % acetic acid) and phase B (10 % acetonitrile, 0.1 %
FA) were used to establish a 60 min gradient. The eluted
fractions were collected at 1 min intervals, pooled into 26
separate fractions for each sample, then dried and recon-
stituted in 0.1 % FA.
Peptides were separated and analyzed on a Dionex Ultim-
ate 3000 RSLC nanoLC system coupled to a Q-Exactive
apparatus (Thermo Fisher, MA). Approximately 5 μl sam-
ple was injected into an acclaim peptide trap column via
the autosampler of the Dionex RSLC nanoLC system. The
flow rate was set at 300 nl/min. Mobile phase A (0.1 % FA
in 5 % acetonitrile) and mobile phase B (0.1 % FA in aceto-
nitrile) were used to establish a 60 min gradient. Peptides
were then analyzed on a Dionex EASY-spray column
(PepMap® C18, 3um, 100A) using an EASY nanospray
source at an electrospray potential of 1.5 kV. A full MS scan
(350–1600 m/z range) was acquired at a resolution of
70,000 at m/z 200, with a maximum ion accumulation time
of 100 ms. Dynamic exclusion was set to 30 s. Resolution
for MS/MS spectra was set to 35,000 at m/z 200. The AGC
setting was 1E6 for the full MS scan and 2E5 for the MS2
scan. The 10 most intense ions above a 1000 count thresh-
old were selected for HCD fragmentation, with a maximum
ion accumulation time of 120 ms. An isolation width of
2 Da was used for the MS2 scan. Single and unassigned
charged ions were excluded from MS/MS. For HCD, nor-
malized collision energy was set to 28. The underfill ratio
was defined as 0.1 %.
Data analysis
Raw data files were converted into the mascot generic
file format using Proteome Discoverer version 1.4
(Thermo Electron, Bremen, Germany) with the MS2
spectrum processor for de-isotoping the MS/MS spectra.
The concatenated target-decoy UniProt human database
(sequence 88 473, downloaded on 29 November 2013)
was used for data searches. The database search was per-
formed using an in-house Mascot server (version 2.4.1,
Matrix Science, Boston, MA) with MS tolerance of
5.1 ppm and MS/MS tolerance of 0.02 Da. Two missed
trypsin cleavage sites per peptide were tolerated. Carba-
midomethylation (C) was set as a fixed modification,
while oxidation (M) and deamidation (N and Q) were
variable modifications. Annotated MS/MS spectra of
Mascot-detected deamidated peptides were exported
and showed in Supplementary data (Annotated MS_MS
spectra _Mascot). Data were then searched again using
the same criteria in MaxQuant (version 1.5.2.8) [50] to
ensure maximum confidence protein identification,
quantification and assessment of deamidation status. In
Mascot, label-free quantitation (LFQ) of proteins uses
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emPAI [51], which is based on spectral counting,
whereas LFQ in Maxquant is based on the ion intensities
of the extracted ion chromatogram [52]. For the first
search, peptide mass tolerances were 20 ppm and
4.5 ppm respectively, whereas for MS/MS the threshold
was 20 ppm with FTMS de-isotoping enabled. The
search was performed in revert decoy mode with PSM
FDR, protein FDR and site decoy fraction set at 0.01.
Annotated MS/MS spectra of Andromeda-detected dea-
midated peptides were exported and showed in Supple-
mentary data (Annotated MS_MS spectra_Maxqunat).
Proteins were considered for further analysis only when
identified by both software packages as displaying differ-
ential abundance in the soluble and aggregated fractions,
and featured deamidation sites that were consistently
identified by both search engines.
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cation) have been deposited to the ProteomeXchange
Consortium [53] via the PRIDE partner repository with
the dataset identifier PXD002516.
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(aggregated) fractions by Maxquant. Table S1D. Human proteins
enriched in aggregated fraction as identified mainly in pellet
(aggregated) fraction by Maxquant. Table S1E. Unique deamidated
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